A New Target for Protecting the Optic Nerve? Human Glaucoma Study Strengthens the Case Against Galectin-3

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/a-new-target-for-protecting-the-optic-nerve-human-glaucoma-study-strengthens-the-case-against-galectin-3Test your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:A New Target for Protecting the Optic Nerve? Human Glaucoma Study Strengthens the Case Against Galectin-3 Introduction Galectin-3 inhibition is becoming one of the more credible new neuroprotective strategies in glaucoma—but it is not yet a proven treatment, and it is not ready to replace intraocular pressure lowering. The reason for the growing interest is that Galectin-3 sits at the intersection of several processes implicated in glaucoma: Microglial activation Müller glial stress responses Astrocyte reactivity Neuroinflammation Phagocytosis and debris clearance Metabolic dysfunction Retinal ganglion-cell and optic-nerve injury Earlier animal studies showed that genetic removal or pharmacological inhibition of Galectin-3 could preserve retinal ganglion cells and their axons despite continued ocular hypertension. A later rat study confirmed that intravitreal TD139, a small-molecule Galectin-3 inhibitor, protected retinal ganglion cells without lowering intraocular pressure. () The important new development is the demonstration that Galectin-3 is strongly associated with Müller glia in human glaucomatous retinas, rather than being merely a marker of activated microglia in experimental animals. The human finding makes the target more biologically relevant to patients, but it also makes the biology more complicated: Galectin-3 may be harmful in some disease-associated microglia while supporting beneficial Müller-cell functions in other circumstances. An Important Evidence Check: What Was Actually Published? As of August 17, 2026, the directly verifiable record matching the human Müller-glia finding is an EVER 2025 abstract by Anne Rombaut and colleagues titled Galectin-3 is associated with Müller cells in glaucoma. I could not independently verify the exact full-text August 2026 Acta Neuropathologica Communications citation described in the prompt through the indexed records available for this review. That distinction matters. The abstract provides the central findings, but it does not provide all the information normally expected from a complete research article, such as the full donor characteristics, exact sample sizes, fold changes, complete statistical tables, and detailed limitations. The conclusions below therefore separate: Human tissue findings that are directly reported in the abstract Animal treatment findings from peer-reviewed studies Reasonable but still unproven interpretations The human findings are nevertheless important because they connect the Galectin-3 pathway to the cell type that spans almost the entire retina and supports retinal ganglion-cell metabolism and homeostasis. () What Researchers Found in Human Glaucomatous Retinas Galectin-3 increased in association with glial markers Rombaut and colleagues examined Galectin-3 staining in: A rat bead model of ocular hypertension at an early time point and an early degenerative time point Donor human retinas with late-stage glaucoma Cell cultures of human MIO-M1 Müller glial cells They compared Galectin-3 with: Iba-1, a marker used to identify microglia and infiltrating monocyte-lineage cells Glial fibrillary acidic protein, a marker expressed by reactive astrocytes and Müller glia In the experimental rat retinas, the volume of Galectin-3 staining and its overlap with both the microglial marker and the glial fibrillary acidic protein marker increased. In the human retinas, however, Galectin-3 was more strongly associated with the glial fibrillary acidic protein-positive compartment. This Galectin-3–glial fibrillary acidic protein association was present in both control and glaucomatous retinas but was significantly greater in glaucoma. The authors interpreted this as evidence of a strong Müller-glial response. () What about microglia and astrocytes? The findings do not mean that microglia or astrocytes are irrelevant. Previous glaucoma studies have shown: Microglial activation in human glaucomatous retinas and optic nerves Increased Galectin-3 expression in disease-associated microglia in experimental glaucoma Increased astrocyte reactivity and Galectin-3 expression in the optic nerve head Increased Galectin-3 in human glaucomatous optic nerve head tissue and trabecular meshwork In the human Müller-cell study, glial fibrillary acidic protein was used as a combined marker for astrocytes and Müller glia. Therefore, glial fibrillary acidic protein staining alone cannot perfectly separate these two cell types. Morphological localization and the authors’ interpretation support a major Müller-glial contribution, but the full paper should provide more definitive cell-specific confirmation using markers such as retinaldehyde-binding protein 1, glutamine synthetase, cellular retinaldehyde-binding protein, or other Müller-cell markers. () The most important human observation The key observation is not simply that “Galectin-3 is higher in glaucoma.” It is that Galectin-3 appears to be redistributed toward Müller glia in human glaucoma, while also being associated with microglia and astrocytes. That is important because Müller glia: Extend through almost the full thickness of the retina Regulate potassium and water balance Remove excess glutamate Provide metabolic substrates to neurons Support the blood-retinal barrier Respond rapidly to mechanical, metabolic, and inflammatory stress Communicate with retinal ganglion cells, microglia, blood vessels, and other retinal cells A dysfunctional Müller cell can therefore influence many retinal systems at once. () Why the Müller-Glia Association Matters Müller glia can protect retinal ganglion cells—or amplify injury Healthy Müller glia are essential support cells. They help maintain the environment in which retinal ganglion cells function. In glaucoma, this support system can become disturbed. Experimental and review literature suggests that stressed Müller glia may: Release adenosine triphosphate, which can activate purinergic receptors Increase inflammatory signaling Alter glutamate handling Lose efficient potassium buffering Change their metabolism Release tumor necrosis factor alpha and interleukin-6 Promote microglial activation Contribute to a feed-forward inflammatory loop Müller-glia-derived adenosine triphosphate can act directly on retinal ganglion cells or stimulate microglia to release inflammatory mediators. This provides a possible route through which Müller glia could contribute to retinal ganglion-cell dysfunction even before extensive neuronal death has occurred. () Galectin-3 could be a signaling amplifier Galectin-3 is a carbohydrate-binding protein that can function inside cells, on cell surfaces, or in the extracellular environment. It can influence: Cell adhesion Cell migration Immune activation Phagocytosis Cell survival Fibrosis Cytokine signaling Receptor clustering and signaling In disease-associated microglia, Galectin-3 is often part of a broader program involving apolipoprotein E, lysosomal activity, phagocytosis, and inflammatory remodeling. In glaucoma models, Galectin-3 appears to help maintain a microglial state that can damage retinal ganglion cells. () The Müller-cell response may not be conventionally inflammatory One of the most interesting findings from the Rombaut group’s cell-culture experiments was that recombinant Galectin-3 caused morphological changes in MIO-M1 Müller cells consistent with gliosis. However, the molecular response was different from the response caused by a mixture of tumor necrosis factor alpha, interleukin-1 alpha, and complement component 1q. The inflammatory control mixture produced extensive inflammatory gene activation. Galectin-3 caused more modest changes, including effects that appeared to reduce some inflammatory signaling and alter Müller-cell homeostatic responses. This suggests that Galectin-3 may not simply be a conventional inflammatory trigger in Müller cells. It may instead act as a stress-response regulator, changing the behavior of Müller glia in ways that can be protective, maladaptive, or both depending on disease stage and cellular context. () Is Galectin-3 Harmful, Protective, or Merely a Marker? The most accurate answer is: potentially all three, depending on where, when, and how it is expressed. Evidence that Galectin-3 can be harmful In experimental glaucoma: Galectin-3 is increased in activated, disease-associated microglia Genetic deletion of the Galectin-3 gene protects retinal ganglion cells TD139 protects retinal ganglion cells despite continued ocular hypertension Galectin-3 inhibition can protect optic-nerve axons in mouse models These intervention studies support more than a simple marker role. They indicate that at least some forms of Galectin-3 signaling contribute causally to neurodegeneration. () Evidence that Galectin-3 can also be protective Other retinal studies show that Galectin-3 helps Müller glia perform clearance phagocytosis through the MERTK receptor pathway. In those studies, Galectin-3 deficiency worsened Müller-cell activation and aggravated retinal degeneration in inherited and chemically induced retinal injury models. This is an important warning. Completely eliminating Galectin-3 from every retinal cell may not be beneficial. MüSupport the show